ONO PHARMACEUTICAL CO., LTD. Logo

ONO PHARMACEUTICAL CO., LTD.

Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.

4528 | T

Overview

Corporate Details

ISIN(s):
JP3197600004
LEI:
Country:
Japan
Address:
大阪市中央区道修町二丁目1番5号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ONO PHARMACEUTICAL CO., LTD., established in 1717, is a research and development-oriented pharmaceutical company dedicated to discovering and delivering innovative medicines. With a legacy spanning over three centuries, the company focuses on addressing high unmet medical needs through the creation, manufacturing, and sale of prescription drugs. Its primary therapeutic areas include oncology, immunology, neurology, and other specialty fields, with a portfolio of treatments for conditions such as cancer and type II diabetes. The company is committed to a mission of fighting disease and pain by providing new therapeutic options to patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 01:00
Registration Form
確認書
Japanese 9.1 KB
2025-11-06 01:00
Interim Report
半期報告書-第78期(2025/04/01-2026/03/31)
Japanese 328.6 KB
2025-07-01 09:06
Registration Form
確認書
Japanese 9.2 KB
2025-07-01 09:00
Annual Report
訂正有価証券報告書-第77期(2024/04/01-2025/03/31)
Japanese 1.3 MB
2025-06-20 02:00
Post-Annual General Meeting Information
臨時報告書
Japanese 25.3 KB
2025-06-19 09:06
Share Issue/Capital Change
臨時報告書
Japanese 39.9 KB
2025-06-19 09:05
Share Issue/Capital Change
臨時報告書
Japanese 41.7 KB
2025-06-19 09:02
Governance Information
内部統制報告書-第77期(2024/04/01-2025/03/31)
Japanese 26.0 KB
2025-06-19 09:01
Registration Form
確認書
Japanese 9.2 KB
2025-06-19 09:00
Annual Report
有価証券報告書-第77期(2024/04/01-2025/03/31)
Japanese 2.5 MB
2024-11-06 01:00
Interim Report
半期報告書-第77期(2024/04/01-2025/03/31)
Japanese 334.0 KB
2024-11-06 01:00
Interim Report
確認書
Japanese 9.1 KB
2024-06-21 02:05
Post-Annual General Meeting Information
臨時報告書
Japanese 27.2 KB
2024-06-21 02:04
Governance Information
内部統制報告書-第76期(2023/04/01-2024/03/31)
Japanese 24.4 KB
2024-06-21 02:03
Registration Form
確認書
Japanese 9.2 KB

Automate Your Workflow. Get a real-time feed of all ONO PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ONO PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ONO PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.